---
title: "Tango Therapeutics Announces Executive Chair Transition | TNGX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295154714.md"
description: "Tango Therapeutics (NASDAQ: TNGX) announced that Dr. Barbara Weber will step down as Executive Chairman of the Board to pursue other interests. President Dr. Malte Peters expressed gratitude for her vision and leadership, stating the company is well-positioned for future success. This transition marks a change in corporate governance for the clinical-stage biotechnology firm focused on precision cancer medicines."
datetime: "2026-08-06T14:24:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295154714.md)
  - [en](https://longbridge.com/en/news/295154714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295154714.md)
generator: "portal-rs"
---

# Tango Therapeutics Announces Executive Chair Transition | TNGX Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.

“I am proud with what we have achieved at Tango and am confident that the Company is extremely well positioned to build on those achievements,” Dr. Weber said.

“The Company is profoundly grateful to Dr. Weber for all that she has brought to it: vision, leadership, passion for Tango and its employees and commitment to the groundbreaking work we are doing,” said Tango President Dr. Malte Peters.

**About Tango Therapeutics**  
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

**Forward-Looking Statements**  
Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding Forward-looking statements are not purely historical and may be accompanied by words such as “may,” “should,” “expect,” “intend,” “plan,” “will,” “goal,” “estimate,” “anticipate,” “believe,” “predict,” “designed,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology. 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond Tango’s control, and actual results could differ materially from those expressed or implied by these statements. These risks and uncertainties include, among others, risks related to drug development, clinical trials, regulatory review and approval, commercialization, competition, financing and Tango’s ability to execute its business strategy. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

**Investors:**  
Elizabeth Hickin  
ehickin@tangotx.com

**Media:**  
1AB  
Amanda Lazaro  
amanda@1abmedia.com

### Related Stocks

- [TNGX.US](https://longbridge.com/en/quote/TNGX.US.md)

## Related News & Research

- [Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX](https://longbridge.com/en/news/295773782.md)
- [Tango Therapeutics ajukan program penjualan saham at-the-market hingga USD 400 juta](https://longbridge.com/en/news/295581692.md)
- [Tango Therapeutics Q2 net loss widens as expenses rise](https://longbridge.com/en/news/295526669.md)
- [Tango Therapeutics President, R&D Crystal Adam disposes of USD 734,514 common shares](https://longbridge.com/en/news/295005668.md)
- [Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | TNGX Stock News](https://longbridge.com/en/news/286309850.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**